EXHIBIT 99.1

[htbx_ex99z1001.jpg]


Heat Biologics Reports Third Quarter 2019 Results
and Provides Corporate Update


Reported positive Phase 2 interim data in advanced non-small cell lung cancer patients


MORRISVILLE, NC – November 15, 2019

– Heat Biologics, Inc. (Nasdaq: HTBX), a biopharmaceutical company developing therapeutics designed to activate a patient’s immune system against cancer, today reported financial and clinical updates for the third quarter ended September 30, 2019.

Jeff Wolf, Heat's CEO, commented, “We remain encouraged by the positive top line data from our Phase 2 trial for HS-110 in advanced non-small cell lung cancer (NSCLC) in combination with Bristol-Myers Squibb's anti-PD-1 checkpoint inhibitor, Opdivo® (nivolumab) and with Merck’s anti-PD-1 checkpoint inhibitor Keytruda® (pembrolizumab), which completed enrollment in July 2019. We recently presented a subset of this data in a poster presentation at The Society of Immunotherapy of Cancer’s (SITC) 34th Annual Meeting, in which we reported that 61% of patients in our Phase 2 Cohort B achieved disease stabilization per iRECIST, a patient population whose disease had progressed following prior checkpoint inhibitor therapy. Based on this data, we look forward to advancing our clinical trials and intend to aggressively explore all options for the future development of HS-110, including possible collaboration and licensing opportunities.”

“We ended the quarter with approximately $15.0 million in cash, cash equivalents and short-term investments. We believe we are well funded to advance our clinical activities though additional major milestones and continue to manage expenses accordingly.

Third Quarter 2019 Financial Results


·

Research and development expenses decreased to $3.1 million for the quarter ended September 30, 2019 compared to $4.4 million for the quarter ended September 30, 2018. The decrease of approximately $1.3 million is due to the lower PTX-35 expense for 2019, primarily reflecting decreased manufacturing costs, offset by increased Phase 2 trial expenses, including outsourced clinical trial support services and payments to investigator sites.

·

General and administrative expense increased to $2.0 million for the quarter ended September 30, 2019 compared to $1.6 million for the quarter ended September 30, 2018. The $0.4 million increase is primarily attributable to increased personnel costs, including stock-based compensation expense.

·

Net loss attributable to Heat Biologics was approximately $6.2 million, or ($0.18) per basic and diluted share for the quarter ended September 30, 2019 compared to a net loss of approximately $3.7 million, or ($0.16) per basic and diluted share for the quarter ended September 30, 2018.  

·

As of September 30, 2019, the Company had approximately $15.0 million in cash, cash equivalents and short-term investments with an additional $6.9 million in grant funds from Cancer Prevention Research Institute of Texas (CPRIT) that it expects to receive after filing an IND for PTX-35.





 


About Heat Biologics, Inc.

Heat Biologics is a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer using CD8+ "Killer" T-cells. HS-110 is the Company’s first biologic product candidate in a series of proprietary immunotherapies designed to stimulate a patient's own T-cells to attack cancer. Heat has completed enrollment in its Phase 2 clinical trial for advanced non-small cell lung cancer, in combination with Bristol-Myers Squibb's nivolumab (Opdivo®) or with Merck's pembrolizumab (Keytruda®). Pelican Therapeutics, a subsidiary of Heat, is focused on the development of co-stimulatory monoclonal antibody and fusion protein-based therapies designed to activate the immune system. Heat also has numerous pre-clinical programs at various stages of development. For more information, please visit www.heatbio.com.


Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These statements are based upon current beliefs, expectations and assumptions and include statements such as: looking forward to  advancing Heat’s clinical trials, the intention to aggressively explore all options for the future development of HS-110, including possible collaboration and licensing opportunities, being well funded to advance Heat’s clinical activities through additional major milestones and continuing to manage expenses accordingly, and the expected receipt of an additional $6.9 million in grant funds from CPRIT after filing the IND for PTX-35  These statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements, including the ability of Heat’s therapies to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, Heat’s ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Heat’s  ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, Heat’s ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, its ability to retain its key scientists or management personnel, and the other factors described in Heat’s  Annual Report on Form 10-K and  10-K/A  for the year ended December 31, 2018 and other subsequent filings with the SEC.  The information in this release is provided only as of the date of this release and the company undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.


Media and Investor Relations Contact

David Waldman

+1-919-289-4017

investorrelations@heatbio.com

 

(tables follow)




 


HEAT BIOLOGICS, INC.

Consolidated Balance Sheets


 

 

September 30,

2019

 

December 31,

2018

 

 

 

(unaudited)

 

 

 

Current Assets

    

                          

    

                          

  

Cash and cash equivalents

 

$

9,334,421

 

$

22,154,251

 

Short-term investments

 

 

5,683,446

 

 

5,570,027

 

Accounts receivable

 

 

37,300

 

 

28,538

 

Prepaid expenses and other current assets

 

 

734,788

 

 

961,317

 

Total Current Assets

 

 

15,789,955

 

 

28,714,133

 

 

 

 

 

 

 

 

 

Property and Equipment, net

 

 

609,916

 

 

643,146

 

 

 

 

 

 

 

 

 

Other Assets

 

 

 

 

 

 

 

In-process R&D

 

 

5,866,000

 

 

5,866,000

 

Goodwill

 

 

1,452,338

 

 

2,189,338

 

Right-of-use asset

 

 

347,153

 

 

 

Deposits

 

 

386,284

 

 

351,220

 

Total Other Assets

 

 

8,051,775

 

 

8,406,558

 

 

 

 

 

 

 

 

 

Total Assets

 

$

24,451,646

 

$

37,763,837

 

 

 

 

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current Liabilities

 

 

 

 

 

 

 

Accounts payable

 

$

1,944,333

 

$

974,619

 

Deferred revenue

 

 

 

 

1,032,539

 

Contingent consideration, current portion

 

 

1,477,000

 

 

1,187,000

 

Operating lease liability, current portion

 

 

91,068

 

 

 

Accrued expenses and other liabilities

 

 

1,281,911

 

 

1,678,051

 

Total Current Liabilities

 

 

4,794,312

 

 

4,872,209

 

 

 

 

 

 

 

 

 

Long Term Liabilities

 

 

 

 

 

 

 

Contingent consideration

 

 

2,356,515

 

 

1,918,225

 

Deferred tax liability

 

 

361,911

 

 

316,733

 

Deferred revenue, net of current portion

 

 

200,000

 

 

200,000

 

Operating lease liability, net of current portion

 

 

259,222

 

 

 

Other long-term liabilities

 

 

306,235

 

 

213,724

 

Total Liabilities

 

 

8,278,195

 

 

7,520,891

 

 

 

 

 

 

 

 

 

Commitments and Contingencies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders’ Equity

 

 

 

 

 

 

 

Common stock, $.0002 par value; 100,000,000 shares authorized, 33,334,124 and 32,492,144 shares issued and outstanding at September 30, 2019 (unaudited) and December 31, 2018, respectively

 

 

6,822

 

 

6,499

 

Additional paid-in capital

 

 

117,836,082

 

 

114,883,135

 

Accumulated deficit

 

 

(101,261,124

)

 

(84,580,180

)

Accumulated other comprehensive loss

 

 

52,230

 

 

(19,904

)

Total Stockholders’ Equity– Heat Biologics, Inc.

 

 

16,634,010

 

 

30,289,550

 

Non-Controlling Interest

 

 

(460,559

)

 

(46,604

)

Total Stockholders’ Equity

 

 

16,173,451

 

 

30,242,946

 

 

 

 

 

 

 

 

 

Total Liabilities and Stockholders’ Equity

 

$

24,451,646

 

$

37,763,837

 




 


HEAT BIOLOGICS, INC.

Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)


 

 

Three Months Ended,
September 30,

 

 

Nine months Ended,
September 30,

 

 

 

2019

 

2018

 

 

2019

 

2018

 

Revenue:

  

 

                        

    

 

                        

  

  

 

                        

    

 

                        

 

Grant and licensing revenue

 

$

6,439

 

$

1,840,009

 

 

$

1,049,988

 

$

3,735,713

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

3,129,356

 

 

4,403,759

 

 

 

9,725,744

 

 

10,756,485

 

General and administrative

 

 

1,993,136

 

 

1,585,600

 

 

 

7,201,196

 

 

4,727,105

 

Goodwill impairment loss

 

 

737,000

 

 

 

 

 

737,000

 

 

 

Change in fair value of contingent consideration

 

 

502,000

 

 

114,838

 

 

 

728,290

 

 

665,936

 

Total operating expenses

 

 

6,361,492

 

 

6,104,197

 

 

 

18,392,230

 

 

16,149,526

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

 

(6,355,053

)

 

(4,264,188

)

 

 

(17,342,242

)

 

(12,413,813

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

97,415

 

 

83,509

 

 

 

373,060

 

 

131,306

 

Other (expense) income, net

 

 

(73,275

)

 

31,704

 

 

 

(80,539

)

 

153,500

 

Total non-operating income

 

 

24,140

 

 

115,213

 

 

 

292,521

 

 

284,806

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss before income taxes

 

 

(6,330,913

)

 

(4,148,975

)

 

 

(17,049,721

)

 

(12,129,007

)

Income tax benefit (expense)

 

 

 

 

225,389

 

 

 

(45,178

)

 

665,080

 

Net loss

 

 

(6,330,913

)

 

(3,923,586

)

 

 

(17,094,899

)

 

(11,463,927

)

Net loss – non-controlling interest 

 

 

(136,315

)

 

(265,024

)

 

 

(413,955

)

 

(668,219

)

Net loss attributable to Heat Biologics, Inc.

 

$

(6,194,598

)

$

(3,658,562

)

 

$

(16,680,944

)

$

(10,795,708

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per share attributable to Heat Biologics, Inc.—basic and diluted

 

$

(0.18

)

$

(0.16

)

 

$

(0.50

)

$

(0.75

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average number of common shares used in net loss per share attributable to Heat Biologics, Inc.—basic and diluted

 

 

33,650,829

 

 

23,143,952

 

 

 

33,255,535

 

 

14,359,429

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(6,330,913

)

$

(3,923,586

)

 

$

(17,094,899

)

$

(11,463,927

)

Unrealized gain on foreign currency translation

 

 

63,711

 

 

39,377

 

 

 

72,134

 

 

110,648

 

Total other comprehensive loss

 

 

(6,267,202

)

 

(3,884,209

)

 

 

(17,022,765

)

 

(11,353,279

)

Comprehensive loss attributable to non-controlling interest

 

 

(136,315

)

 

(265,024

)

 

 

(413,955

)

 

(668,219

)

Comprehensive loss

 

$

(6,130,887

)

$

(3,619,185

)

 

$

(16,608,810

)

$

(10,685,060

)








View differences made from one to another to evaluate Heat Biologics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Heat Biologics, Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Log in with your credentials

or    

Forgot your details?

Create Account